Generics applications under review by EMA – January 2021

Genéricos/General | Posted 22/01/2021 post-comment0 Post your comment

Generic medicines in Europe can be approved either centrally via the European Medicines Agency (EMA) or nationally via the local regulatory body [1]. Approval by EMA takes place by using a centralized procedure. This leads to approval of the product in all 28 European Union (EU) Member States and in Iceland, Liechtenstein and Norway. At a country level, if approval in a single EU Member State only is required, this can take place using the national procedure. However, as soon as a company seeks approval in two or more Member States, a decentralized procedure or mutual recognition procedure must be used [2].

EMA logo 2 V13F14

According to EMA’s list of applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP) released on 7 January 2021, the agency is currently reviewing 25 applications for marketing approval in the EU for generics.

The applications include six for antineoplastic (anticancer) medicines (dasatinib, doxorubicin, imatinib, and thiotepa); one for antithrombotic medicine rivaroxaban; one for a diagnostic medicine ioflupane (123I); four for endocrine therapies (abiraterone and leuprorelin); two for immunosuppressants (azathioprine and fingolimod) and one for psycholeptic risperidone. There are already generics of these drugs approved by EMA for all EU countries, see Table 1.

Table 1: Generics under review by EMA*
Common name Therapeutic area Number of applications EMA-approved originator(s) Originator company(ies)
Abiraterone Endocrine therapy 3 Zytiga Janssen-Cilag International
Azathioprine Immunosuppressant 1 Azasan/Imuran/Imurel
Betaine Alimentary tract and metabolism (homocystinuria) 1 Cystadane Recordati Rare Diseases
Dabigatran Antithrombotic medicine 1 Pradaxa Boehringer Ingelheim
Dasatinib Antineoplastic medicine (anticancer) 2 Sprycel Bristol-Myers Squibb
Dexamethasone# Corticosteroid for systemic use (macular oedema/ uveitis and multiple myeloma) 1 Dexdor Orion
Doxorubicin Antineoplastic medicine (anticancer) 2 Caelyx/Myocet Janssen-Cilag/ Teva Pharmaceutical Industries
Fingolimod Immunosuppressant (multiple sclerosis) 1 Gilenya Novartis
Icatibant Haematological medicine (hereditary angioedema) 1 Firazyr Shire Pharmaceuticals
Imatinib Antineoplastic medicine (anticancer) 1 Glivec Novartis
Ioflupane (123I) Diagnostic radiopharmaceutical 1 DaTscan GE Healthcare
Leuprorelin Endocrine therapy 1
Metformin/ sitagliptin Diabetes 1 Efficib/Janumet/Ristfor/Velmetia Merck Sharp and Dohme
Risperidone Psycholeptic 1
Rivaroxaban Antithrombotic medicine 1 Xarelto Bayer
Sildenafil Urological 1

Viagra

Revatio

Pfizer

Upjohn

Sitagliptin Diabetes 2

Januvia/Ristaben/Tesavel/

Xelevia

Merck Sharp and Dohme
Sugammadex Therapeutic medicine (reversal of anaesthesia) 1 Bridion Merck Sharp and Dohme
Thiotepa Antineoplastic medicine (anticancer) 1 Tepadina Adienne
Vildagliptin/ metformin Diabetes 1 Eucreas/Icandra/Zomarist Novartis
Total   25    

*Data collected on 12 January 2021.

#Accelerated timetable for COVID-19-related medicine.

Source: EMA.

First-time pan-European generics under review by EMA include one for a generic version of Cystadane (betaine) for the treatment of Homocystinuria (a rare inherited disorder of the amino acid methionine); one for a generic version of anticoagulant Pradaxa (dabigatran); one for a generic version of corticosteroid Dexdor (dexamethasone) for the treatment of COVID-19 patients; one for a generic version of Firazyr (icatibant) for the treatment of hereditary angioedema (a disorder that causes severe swelling); one for generic version of urological drug Viagra/Revatio (sildenafil); one for a generic version of anaesthesia reversal medicine Bridion (sugammadex) and five for generic versions of diabetes medicines (sitagliptin, metformin/sitagliptin and vildagliptin/metformin).

Since the last report entitled Generics applications under review by EMA – July 2020 by GaBI Online, EMA has approved one generic version of psycholeptic aripiprazole; four generic anticancer medications (arsenic trioxide, erlotinib, melphalan and sunitinib); one generic version of psychoanaleptic (caffeine citrate); one generic treatment for multiple sclerosis (fampridine); one generic immunosuppressant drug (lenalidomide); one generic endocrine therapy (leuprorelin); one generic diagnostic medicine (methylthioninium chloride) and one generic antithrombotic medicine (rivaroxaban).

EMA’s CHMP recommended approval of arsenic trioxide medac for the treatment of acute promyelocytic leukaemia (blood cancer) and fampridine Accord for the treatment of multiple sclerosis in July 2020 [3].

Lenalidomide Mylan was approved by EMA’s CHMP for the treatment of multiple myeloma and follicular lymphoma in November 2020 [4].

Related articles
Biosimilars applications under review by EMA – January 2021

Generics applications under review by EMA – July 2020

LATIN AMERICAN FORUM – Coming soon!

To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

 

LATIN AMERICAN FORUM – Próximamente!

Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

References
1. GaBI Online - Generics and Biosimilars Initiative. EU guidelines for generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 22]. Available from: www.gabionline.net/Guidelines/EU-guidelines-for-generics  
2. GaBI Online - Generics and Biosimilars Initiative. Registration procedures for generic drugs in the EU [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jan 22]. Available from: www.gabionline.net/Reports/Registration-procedures-for-generic-drugs-in-the-EU  
3. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval for arsenic trioxide and fampridine generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 22]. Available from: www.gabionline.net/Generics/News/EMA-recommends-approval-for-arsenic-trioxide-and-fampridine-generics 
4. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of Lenalidomide Mylan [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 22]. Available from: www.gabionline.net/Generics/News/EMA-recommends-approval-of-Lenalidomide-Mylan

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: EMA

comment icon Comments (0)
Post your comment
Related content
New five-year medicines agreements in Australia
24-AA011041
Genéricos/General Posted 24/09/2021
Generics applications under review by EMA – July 2021
EMA logo 2 V13F14
Genéricos/General Posted 23/07/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010